- Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues.
- Coexistence of chronic myeloid leukemia and hairy cell leukemia of common clonal origin.
- [Pancytopenia and focal splenic lesions in an 80-year-old man. Hairy cell leukemia]
- Effective treatment of autoimmune hemolytic anemia and hairy cell leukemia with interferon-alpha.
Table of Contents
1
UI - 11994981
AU - Larsen CR; Hansen PB; Clausen NT
TI -
Aggressive growth of epithelial carcinomas following treatment with
nucleoside analogues.
SO - Am J Hematol 2002 May;70(1):48-50
AD - Department of Internal Medicine F, Section of Hematology and Oncology,
Hillerod Hospital, Hillerod, Denmark. rifbjerg@dadlnet.dk
Two patients, one with B-cell chronic lymphocytic leukemia (CLL) and one
with hairy-cell leukemia (HCL), were treated with immunosuppressive
chemotherapy. The patient with CLL was a 54-year-old female, who had had
a squamous cell carcinoma (SCC) excised from her forehead 5 months
before receiving the first course of fludarabine. During the fludarabine
treatment, the patient developed a local SCC relapse and metastases in
the neck. The carcinoma was treated by excision and radiotherapy, and
further fludarabine treatment was withheld. Nevertheless, the SCC
metastasized aggressively and the patient died 3 months after the start
of fludarabine treatment, primarily due to respiratory failure. The
autopsy revealed heavy SCC infiltrations involving the lungs, pleura,
mediastinum, pericardium, and liver. The patient with HCL was a
69-year-old male. At the time of diagnosis of HCL, the patient had two
solid tumors in the liver containing poorly differentiated epithelial
carcinoma cells of unknown origin. During treatment with
2-chlorodeoxyadenosine (2CdA), the tumors in the liver rapidly spread in
multiple intrahepatic metastases, followed by liver failure and death
within 1 month. Fludarabine and 2CdA cause a substantial suppression of
all lymphocyte subsets, in particular the T-cell line. T-lymphocytes are
believed to be responsible for the usually slow growth and the low
metastatic rate of the SCC skin lesions. It is therefore assumed that
fludarabine and 2CdA in these two cases triggered an exacerbation of
both tumors due to the T-cell depletion. Copyright 2002 Wiley-Liss, Inc.
2
UI - 12034522
AU - Pajor L; Kereskai L; Tamaska P; Vass JA; Radvanyi G
TI -
Coexistence of chronic myeloid leukemia and hairy cell leukemia of
common clonal origin.
SO - Cancer Genet Cytogenet 2002 Apr 15;134(2):114-7
AD - Department of Pathology, Medical Faculty, University of Pecs, Pecs,
Hungary. pajor@pathology.pote.hu
The history of a forty year old patient is presented who was admitted
with a clinical picture of chronic myeloid leukemia (CML). Laboratory
findings, bone marrow morphology and molecular investigations supported
this diagnosis, including b3/a2 as well as b2/a2 chimeric mRNA
expression in support of a Philadelphia chromosome positive chronic
myeloproliferation. In a fraction of the bone marrow content, however,
an infiltrate different from that of CML could be seen. In addition, the
morphology, cytochemistry, immunophenotyping and molecular analysis
indicated that the coexisting neoplasia is hairy cell leukemia (HCL).
Cell lineage specific interphase cytogenetic analysis proved a clonal
relationship between the two neoplasias in a way that the HCL arose from
one of the B-cells which, based on two cytogenetic markers, belonged to
the original CML clone.
3
UI - 11692413
AU - Nuno Mateo FJ; Noval Menendez J; Llorente de Jesus R; Menendez Calderon
TI -
MJ
[Pancytopenia and focal splenic lesions in an 80-year-old man. Hairy
cell leukemia]
SO - Rev Clin Esp 2001 Sep;201(9):541-2
AD - Servicios de Medicina Interna, Hospital de Cabuenes, Gijon.
4
UI - 11982619
AU - Cesana C; Brando B; Boiani E; Chiodo F; Cairoli R; Intropido L; Morra E
TI -
Effective treatment of autoimmune hemolytic anemia and hairy cell
leukemia with interferon-alpha.
SO - Eur J Haematol 2002 Feb;68(2):120-1
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
About OncoLink Contact OncoLink Privacy statement Disclaimer Link to OncoLink Home